Article Figures & Data
Figures
- Figure 1.
Objective response rates with and without steroid premedication in patients treated with enfortumab vedotin.
- Figure 2.
Disease control rates with and without steroid premedication in patients treated with enfortumab vedotin.
- Figure 3.
Progression-free survival rates with and without steroid premedication in patients treated with enfortumab vedotin.
- Figure 4.
Incidence of enfortumab vedotin-related cutaneous toxicity (all grade) according to steroid premedication (with and without).
- Figure 5.
Incidence of enfortumab vedotin-related cutaneous toxicity (grade ≥3) according to steroid premedication (with and without).
Tables
In this issue
Jump to section
Related Articles
Cited By...
- Pathologic Complete Response After Enfortumab Vedotin Plus Pembrolizumab in Node-positive Upper Tract Urothelial Carcinoma
- Severe Esophageal Ulceration With Enfortumab Vedotin Plus Pembrolizumab Therapy in Urothelial Carcinoma: A Case Report
- Real-world Outcomes of Enfortumab Vedotin in Elderly Patients With Metastatic Urothelial Carcinoma